Skip Navigation



Nicotine & Tobacco Research Advance Access published online on November 1, 2009
Nicotine & Tobacco Research, doi:10.1093/ntr/ntp162
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Article Summary
Right arrow All Versions of this Article:
ntp162v2    most recent
ntp162v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sood, A.
Right arrow Articles by Hays, J. T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sood, A.
Right arrow Articles by Hays, J. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Sibutramine for weight gain attenuation during smoking cessation with varenicline: A pilot study

Amit Sood, Jon O. Ebbert, Matthew M. Clark, Ivana T. Croghan, Darrell R. Schroeder and J. Taylor Hays

Amit Sood, M.D., M.Sc., General Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN
Jon O. Ebbert, M.D., M.Sc., Primary Care Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN
Matthew M. Clark, Ph.D., L.P. Psi, Psychology, Mayo Clinic College of Medicine, Rochester, MN
Ivana T. Croghan, Ph.D., Nicotine Research Program, Mayo Clinic College of Medicine, Rochester, MN
Darrell R. Schroeder, M.S., Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN
J. Taylor Hays, M.D., General Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN

Corresponding Author: Jon O. Ebbert, M.D., M.Sc., Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA. Telephone: (507) 284-8913; Fax: (507) 284-5370; E-mail: ebbert.jon{at}mayo.edu


  Abstract

Introduction: Weight gain following tobacco abstinence is a significant barrier to cessation. Varenicline is the most effective medication for smoking cessation but does not prevent weight gain. Combining sibutramine and varenicline may facilitate smoking abstinence if weight gain is attenuated.

Methods: Our aim was to assess the safety and efficacy of sibutramine for weight gain prevention among women quitting smoking with varenicline. Ten smokers enrolled in a pilot study of open-label sibutramine and varenicline for 12 weeks.

Results: Participants rated themselves low on appearance evaluation, health evaluation, health orientation, and body-areas satisfaction. Ninety percent reported that they would return to smoking if they gained weight after stopping smoking. For the 6 subjects who met criteria for prolonged abstinence, weight change from baseline to Week 12 (11 weeks after the target quit date) was 0.2 ± 1.3 kg, and the 7-day point-prevalence smoking abstinence rate at Week 12 was 70% (95% CI 35%–93%).

Discussion: Combination therapy with sibutramine and varenicline for weight gain prevention and smoking cessation as an intervention for smokers at risk for relapse to smoking because of weight gain may warrant further investigation.

Received: July 16, 2009; Accepted: September 19, 2009
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.